Rein Therapeutics (NASDAQ:RNTX) Stock Price Up 1.6% – What’s Next?

Shares of Rein Therapeutics Inc. (NASDAQ:RNTX) traded up 1.6% during trading on Friday . The stock traded as high as $1.3451 and last traded at $1.30. 44,298 shares changed hands during trading, a decline of 51% from the average session volume of 90,560 shares. The stock had previously closed at $1.28.

Analysts Set New Price Targets

RNTX has been the subject of a number of research analyst reports. Brookline Capital Acquisition cut Rein Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of Rein Therapeutics in a report on Thursday, January 22nd. Citigroup cut shares of Rein Therapeutics to a “hold” rating in a research report on Wednesday, January 21st. Finally, Wall Street Zen downgraded shares of Rein Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, December 14th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Rein Therapeutics has an average rating of “Hold” and a consensus price target of $8.00.

Rein Therapeutics Trading Up 1.6%

The company has a market capitalization of $34.18 million, a price-to-earnings ratio of -0.49 and a beta of 1.51. The company has a 50 day moving average price of $1.23 and a 200 day moving average price of $1.29.

Institutional Trading of Rein Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. State Street Corp lifted its position in Rein Therapeutics by 374.3% during the 4th quarter. State Street Corp now owns 75,904 shares of the company’s stock valued at $88,000 after purchasing an additional 59,900 shares during the period. Voss Capital LP raised its stake in shares of Rein Therapeutics by 59.2% during the fourth quarter. Voss Capital LP now owns 4,243,969 shares of the company’s stock worth $4,923,000 after buying an additional 1,577,437 shares during the last quarter. Gagnon Securities LLC raised its stake in shares of Rein Therapeutics by 5.0% during the fourth quarter. Gagnon Securities LLC now owns 240,220 shares of the company’s stock worth $279,000 after buying an additional 11,528 shares during the last quarter. Jane Street Group LLC acquired a new position in Rein Therapeutics in the fourth quarter valued at approximately $72,000. Finally, HRT Financial LP bought a new position in Rein Therapeutics in the fourth quarter valued at approximately $38,000. 90.89% of the stock is owned by institutional investors.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.